Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards
Primary Purpose
Diabetes Mellitus Type 2
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Insulin, regular - act rapid
Insulin glulisine, Insulin glargine
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
Inclusion Criteria:
- Patients admitted to internal medicine ward with blood glucose (BG) between 140-400 mg/dl.
- Known history (>6months) of diabetes.
- Aged 18-80 years old.
- Previous therapy including either diet alone or any combination of oral hypoglycemia agents, glucagon-like peptide 1 (GLP-1) analogs and long acting insulin analogs or Neutral Protamine Hagedorn (NPH).
Exclusion Criteria:
- Pregnancy
- Patients with ketoacidosis
- Patients with unknown history of diabetes
- Patients with type 1 diabetes mellitus
- Patients with clinically relevant hepatic disease or renal impairment ( serum creatinine≥2.5 mg/dl)
- Use of corticosteroid therapy
- Patient with any mental disorder preventing him to cooperate and give informed consent.
- Patients on multiple daily doses of insulin regimen.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
sliding scale
basal bolus
Arm Description
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT01594060
First Posted
May 7, 2012
Last Updated
February 27, 2018
Sponsor
HaEmek Medical Center, Israel
1. Study Identification
Unique Protocol Identification Number
NCT01594060
Brief Title
Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards
Official Title
A Randomized, Comparative Study of Basal-bolus Insulin Versus Conventional Sliding-scale Regular Insulin Therapy in Management of Non-critically Ill Patients Hospitalized in the Medical Ward.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HaEmek Medical Center, Israel
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
A comparison of two treatment approaches for hyperglycemia in diabetic patients hospitalized in the medical department. The first approach is called basal-bolus in which 4 insulin shots are given daily ( 3 short acting before meals and one long acting before bed time). The second approach is called sliding scale in which short acting insulin alone is given before meals and before bed time according to the patient's glucose values. The aim is to keep fasting glucose between 140-180 mg/dl.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
sliding scale
Arm Type
Active Comparator
Arm Title
basal bolus
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Insulin, regular - act rapid
Intervention Description
4 shots of regular insulin: 3 before meals and one at bedtime.
Intervention Type
Drug
Intervention Name(s)
Insulin glulisine, Insulin glargine
Intervention Description
1 shot glargine at bedtime 3 shots glulisine before meals
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients admitted to internal medicine ward with blood glucose (BG) between 140-400 mg/dl.
Known history (>6months) of diabetes.
Aged 18-80 years old.
Previous therapy including either diet alone or any combination of oral hypoglycemia agents, glucagon-like peptide 1 (GLP-1) analogs and long acting insulin analogs or Neutral Protamine Hagedorn (NPH).
Exclusion Criteria:
Pregnancy
Patients with ketoacidosis
Patients with unknown history of diabetes
Patients with type 1 diabetes mellitus
Patients with clinically relevant hepatic disease or renal impairment ( serum creatinine≥2.5 mg/dl)
Use of corticosteroid therapy
Patient with any mental disorder preventing him to cooperate and give informed consent.
Patients on multiple daily doses of insulin regimen.
12. IPD Sharing Statement
Learn more about this trial
Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards
We'll reach out to this number within 24 hrs